Physician profile
Khaled Nashar
NPI 1124056122
$198,234.97
in general payments reported to CMS, 2019-2025
13 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $11K · 2021: $11K · 2022: $27K · 2023: $36K · 2024: $20K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Travel and Lodging: $16K · Food and Beverage: $4,141 · Consulting Fee: $1,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $115,915.19 |
| Travel and Lodging | $15,682.82 |
| Food and Beverage | $4,140.70 |
| Consulting Fee | $1,960.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $76,422.01 | 2022-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $61,961.48 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $45,293.11 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13,491.92 | 2022-2023 | |
| Ardelyx, INC. | $248.08 | 2025 | Xphozah 30 Mg |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Medtronic, INC. | $146.90 | 2021 | |
| Astrazeneca Uk Limited | $129.89 | 2025 | Lokelma |
| Mallinckrodt Hospital Products INC. | $124.68 | 2023 | Terlivaz |
| Merck Sharp & Dohme LLC | $119.38 | 2024 | Prevymis |
| Amgen INC. | $109.40 | 2024 | Tavneos |
| Fresenius USA Marketing, INC. | $19.89 | 2025 | Nxstage System One, Liberty Select Cycler |
| Akebia Therapeutics INC | $18.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Nashar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.